1. Hereditary leiomyomatosis and renal cell cancer syndrome - case report and review of the literature
- Author
-
Mara Mădălina Mihai, Simona Fica, Silvius Negoiţă, Calin Giurcaneanu, Irina Ahmed Salem, Liliana Gabriela Popa, and Raluca Lutuc
- Subjects
Embryology ,Pathology ,medicine.medical_specialty ,fumarate hydratase ,Skin Neoplasms ,Case Report ,urologic and male genital diseases ,renal cell cancer ,Germline ,Pathology and Forensic Medicine ,Pheochromocytoma ,Pathogenesis ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Neoplastic Syndromes, Hereditary ,Leiomyomatosis ,leiomyoma ,medicine ,Carcinoma ,Humans ,Adrenal Cortical Hyperplasia ,Uterine leiomyoma ,business.industry ,Cell Biology ,General Medicine ,Middle Aged ,medicine.disease ,030220 oncology & carcinogenesis ,Hereditary leiomyomatosis and renal cell cancer syndrome ,Uterine Neoplasms ,Female ,business ,hereditary leiomyomatosis ,Developmental Biology - Abstract
Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is an exceptionally rare autosomal dominant condition caused by a germline heterozygous mutation of the fumarate hydratase gene. It manifests as multiple piloleiomyomas, associated with numerous, early-onset uterine leiomyomas in female patients, as well as a highly increased risk of renal cell carcinoma (RCC), most often type 2 papillary RCC. HLRCC has been described in association with adrenal cortical hyperplasia, pheochromocytoma, adrenal cortical carcinoma, and other solid tumors, but the exact relationship between these disorders has not yet been clarified. We present a case of HLRCC associated with bilateral adrenal cortical hyperplasia and discuss the pathogenesis, clinical and paraclinical features of HLRCC, as well as the adequate management of these patients.
- Published
- 2021